Oncolytic measles viruses for cancer therapy

Takafumi Nakamura, Stephen J Russell

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

New strategies using biological agents are being developed to treat cancer. Live viruses are among these new agents. Virotherapy uses replication-competent viral vectors with strong oncolytic properties. With the use of molecular virology techniques, viruses have been genetically engineered to replicate selectively in tumour cells and are under preclinical and clinical investigation at present. Measles virus (MV) is being used for this purpose. Replication-competent attenuated Edmonston B measles vaccine strain (MV-Edm) is nonpathogenic and has potent antitumour activity against several human tumours. The virus is selectively oncolytic in tumour cells, eliciting extensive cell-to-cell fusion and ultimately leading to cell death. Therefore, MV-Edm is a safe and efficient means to kill tumour cells. Further improvements in existing MV vectors may increase tumour selectivity and oncolytic activity. This review discusses the discovery and development of replication-competent oncolytic MV for cancer therapy.

Original languageEnglish (US)
Pages (from-to)1685-1692
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume4
Issue number10
DOIs
StatePublished - Oct 2004

Fingerprint

Oncolytic Viruses
Measles virus
Viruses
Tumors
Neoplasms
Cells
Therapeutics
Measles Vaccine
Virology
Cell Fusion
Biological Factors
Cell death
Cell Death
Fusion reactions

Keywords

  • Cancer
  • Oncolytic measles virus
  • Virotherapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology
  • Pharmacology

Cite this

Oncolytic measles viruses for cancer therapy. / Nakamura, Takafumi; Russell, Stephen J.

In: Expert Opinion on Biological Therapy, Vol. 4, No. 10, 10.2004, p. 1685-1692.

Research output: Contribution to journalArticle

@article{dc7220607cb2488da297193aec4f6652,
title = "Oncolytic measles viruses for cancer therapy",
abstract = "New strategies using biological agents are being developed to treat cancer. Live viruses are among these new agents. Virotherapy uses replication-competent viral vectors with strong oncolytic properties. With the use of molecular virology techniques, viruses have been genetically engineered to replicate selectively in tumour cells and are under preclinical and clinical investigation at present. Measles virus (MV) is being used for this purpose. Replication-competent attenuated Edmonston B measles vaccine strain (MV-Edm) is nonpathogenic and has potent antitumour activity against several human tumours. The virus is selectively oncolytic in tumour cells, eliciting extensive cell-to-cell fusion and ultimately leading to cell death. Therefore, MV-Edm is a safe and efficient means to kill tumour cells. Further improvements in existing MV vectors may increase tumour selectivity and oncolytic activity. This review discusses the discovery and development of replication-competent oncolytic MV for cancer therapy.",
keywords = "Cancer, Oncolytic measles virus, Virotherapy",
author = "Takafumi Nakamura and Russell, {Stephen J}",
year = "2004",
month = "10",
doi = "10.1517/14712598.4.10.1685",
language = "English (US)",
volume = "4",
pages = "1685--1692",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Oncolytic measles viruses for cancer therapy

AU - Nakamura, Takafumi

AU - Russell, Stephen J

PY - 2004/10

Y1 - 2004/10

N2 - New strategies using biological agents are being developed to treat cancer. Live viruses are among these new agents. Virotherapy uses replication-competent viral vectors with strong oncolytic properties. With the use of molecular virology techniques, viruses have been genetically engineered to replicate selectively in tumour cells and are under preclinical and clinical investigation at present. Measles virus (MV) is being used for this purpose. Replication-competent attenuated Edmonston B measles vaccine strain (MV-Edm) is nonpathogenic and has potent antitumour activity against several human tumours. The virus is selectively oncolytic in tumour cells, eliciting extensive cell-to-cell fusion and ultimately leading to cell death. Therefore, MV-Edm is a safe and efficient means to kill tumour cells. Further improvements in existing MV vectors may increase tumour selectivity and oncolytic activity. This review discusses the discovery and development of replication-competent oncolytic MV for cancer therapy.

AB - New strategies using biological agents are being developed to treat cancer. Live viruses are among these new agents. Virotherapy uses replication-competent viral vectors with strong oncolytic properties. With the use of molecular virology techniques, viruses have been genetically engineered to replicate selectively in tumour cells and are under preclinical and clinical investigation at present. Measles virus (MV) is being used for this purpose. Replication-competent attenuated Edmonston B measles vaccine strain (MV-Edm) is nonpathogenic and has potent antitumour activity against several human tumours. The virus is selectively oncolytic in tumour cells, eliciting extensive cell-to-cell fusion and ultimately leading to cell death. Therefore, MV-Edm is a safe and efficient means to kill tumour cells. Further improvements in existing MV vectors may increase tumour selectivity and oncolytic activity. This review discusses the discovery and development of replication-competent oncolytic MV for cancer therapy.

KW - Cancer

KW - Oncolytic measles virus

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=5644237829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644237829&partnerID=8YFLogxK

U2 - 10.1517/14712598.4.10.1685

DO - 10.1517/14712598.4.10.1685

M3 - Article

C2 - 15461580

AN - SCOPUS:5644237829

VL - 4

SP - 1685

EP - 1692

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -